1 week Ago By Defense World Staff
Sarepta Therapeutics, Inc. ( NASDAQ:SRPT – Get Free Report ) has earned a consensus rating of “Moderate Buy” from the twenty-two brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nineteen have given a buy recommendation and one has assigned a strong buy recommendation to the company.
The average 12-month price target among analysts that have issued a report on the stock in the last year is $178.71. SRPT has been the topic of a number of research reports.
Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, January 14th. Robert W.
Baird cut their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th.
Piper Sandler dropped their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th.
Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $152.00 to $167.00 in a research report on Thursday, November 7th.
Finally, Raymond James reiterated an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Read Our Latest Research Report on SRPT Sarepta Therapeutics Stock Performance Insider Transactions at Sarepta Therapeutics In related news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction dated Thursday, December 5th.
The shares were sold at an average price of $125.55, for a total value of $205,399.80.
Following the sale, the director now directly owns 5,880 shares in the company, valued at $738,234. The trade was a 21.77 % decrease in their position.
The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink . Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.
84, for a total value of $1,310,820.00. Following the transaction, the director now owns 22,840 shares of the company’s stock, valued at $2,851,345.
60. This represents a 31.49 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Company insiders own 7.70% of the company’s stock.
Institutional Investors Weigh In On Sarepta Therapeutics Several hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP increased its holdings in shares of Sarepta Therapeutics by 32.3% during the 3rd quarter.
Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after buying an additional 665,087 shares during the last quarter. Erste Asset Management GmbH acquired a new position in Sarepta Therapeutics in the third quarter worth about $79,425,000. Janus Henderson Group PLC boosted its holdings in Sarepta Therapeutics by 14.
2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after purchasing an additional 543,143 shares during the period. Soros Fund Management LLC acquired a new position in Sarepta Therapeutics in the third quarter valued at approximately $25,800,000.
Finally, Swedbank AB bought a new stake in Sarepta Therapeutics in the 4th quarter valued at about $16,706,000. Institutional investors and hedge funds own 86.68% of the company’s stock.
Sarepta Therapeutics Company Profile ( Get Free Report Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. Featured Stories Five stocks we like better than Sarepta Therapeutics How to Use Stock Screeners to Find Stocks Bloom Energy: Powering the Future With Decentralized Energy Learn Technical Analysis Skills to Master the Stock Market Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul What Does Downgrade Mean in Investing? Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
